Foundation Medicine Stock Price, News & Analysis (NASDAQ:FMI)

$50.20 0.95 (1.93 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$50.20
Today's Range$50.20 - $47.85
52-Week Range$17.10 - $55.95
Volume141,733 shs
Average Volume220,878 shs
Market Capitalization$1.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.09

About Foundation Medicine (NASDAQ:FMI)

Foundation Medicine logoFoundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer. Its suite of clinical molecular information products includes FoundationOne, which is used for solid tumors; FoundationOne Heme, which is used for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma, pediatric cancers and advanced sarcoma; FoundationACT (Assay for Circulating Tumor DNA), which is a blood-based (liquid biopsy) assay that evaluates circulating tumor deoxyribonucleic acid (ctDNA), and FoundationFocus CDxBRCA, which is a companion diagnostic assay to aid in identifying women with ovarian cancer for whom treatment with Rubraca (rucaparib).


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:FMI
  • CUSIP: N/A
  • Web: www.foundationmedicine.com
Debt:
  • Debt-to-Equity Ratio: 0.47%
  • Current Ratio: 2.24%
  • Quick Ratio: 2.03%
Sales & Book Value:
  • Annual Sales: $116.86 million
  • Price / Sales: 15.57
  • Book Value: $1.75 per share
  • Price / Book: 28.69
Profitability:
  • Trailing EPS: ($4.47)
  • Net Income: ($113,190,000.00)
  • Net Margins: -119.69%
  • Return on Equity: -143.18%
  • Return on Assets: -93.58%
Misc:
  • Employees: 535
  • Outstanding Shares: 36,250,000
 

Frequently Asked Questions for Foundation Medicine (NASDAQ:FMI)

What is Foundation Medicine's stock symbol?

Foundation Medicine trades on the NASDAQ under the ticker symbol "FMI."

How were Foundation Medicine's earnings last quarter?

Foundation Medicine, Inc. (NASDAQ:FMI) posted its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.90) EPS for the quarter, topping analysts' consensus estimates of ($1.06) by $0.16. The firm earned $42.66 million during the quarter, compared to analysts' expectations of $37.99 million. Foundation Medicine had a negative return on equity of 143.18% and a negative net margin of 119.69%. The firm's quarterly revenue was up 45.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.90) EPS. View Foundation Medicine's Earnings History.

Where is Foundation Medicine's stock going? Where will Foundation Medicine's stock price be in 2017?

3 brokers have issued twelve-month target prices for Foundation Medicine's shares. Their predictions range from $31.00 to $39.00. On average, they expect Foundation Medicine's stock price to reach $35.00 in the next twelve months. View Analyst Ratings for Foundation Medicine.

Who are some of Foundation Medicine's key competitors?

Who are Foundation Medicine's key executives?

Foundation Medicine's management team includes the folowing people:

  • Michael J. Pellini M.D., Chairman of the Board (Age 52)
  • Steven J. Kafka Ph.D., President, Chief Operating Officer (Age 47)
  • Troy Cox, Chief Executive Officer, Director (Age 53)
  • Jason Ryan, Chief Financial Officer, Principal Financial Officer, Principal Accounting officer (Age 42)
  • Robert Hesslein, Senior Vice President, General Counsel (Age 63)
  • Tom Civik, Chief Commercial Officer (Age 48)
  • Vincent Miller M.D., Chief Medical Officer (Age 55)
  • Alexis Borisy, Director (Age 45)
  • Daniel O. Day, Director (Age 52)
  • Michael R. Dougherty, Director (Age 59)

Who owns Foundation Medicine stock?

Foundation Medicine's stock is owned by many different of institutional and retail investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (4.20%), Chevy Chase Trust Holdings Inc. (2.92%), Discovery Group I LLC (2.31%), Oppenheimer & Co. Inc. (2.00%), Peregrine Capital Management LLC (0.92%) and Amundi Pioneer Asset Management Inc. (0.91%). Company insiders that own Foundation Medicine stock include David Daly, Jason Ryan, Krishna Yeshwant, Michael J Pellini, Robert W Hesslein, Steven J Kafka and Vincent A Miller. View Institutional Ownership Trends for Foundation Medicine.

Who sold Foundation Medicine stock? Who is selling Foundation Medicine stock?

Foundation Medicine's stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Amundi Pioneer Asset Management Inc., Pier Capital LLC, IFP Advisors Inc and California State Teachers Retirement System. Company insiders that have sold Foundation Medicine company stock in the last year include David Daly, Jason Ryan, Krishna Yeshwant, Michael J Pellini, Robert W Hesslein, Steven J Kafka and Vincent A Miller. View Insider Buying and Selling for Foundation Medicine.

Who bought Foundation Medicine stock? Who is buying Foundation Medicine stock?

Foundation Medicine's stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Oppenheimer & Co. Inc., Macquarie Group Ltd., Chevy Chase Trust Holdings Inc., Zurcher Kantonalbank Zurich Cantonalbank, Baillie Gifford & Co., Discovery Group I LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Foundation Medicine.

How do I buy Foundation Medicine stock?

Shares of Foundation Medicine can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Foundation Medicine's stock price today?

One share of Foundation Medicine stock can currently be purchased for approximately $50.20.

How big of a company is Foundation Medicine?

Foundation Medicine has a market capitalization of $1.79 billion and generates $116.86 million in revenue each year. The company earns ($113,190,000.00) in net income (profit) each year or ($4.47) on an earnings per share basis. Foundation Medicine employs 535 workers across the globe.

How can I contact Foundation Medicine?

Foundation Medicine's mailing address is 150 2nd St, CAMBRIDGE, MA 02141-2115, United States. The company can be reached via phone at +1-617-4182200 or via email at [email protected]


MarketBeat Community Rating for Foundation Medicine (NASDAQ FMI)

Community Ranking:  1.3 out of 5 (star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  247 (Vote Underperform)
Total Votes:  337
MarketBeat's community ratings are surveys of what our community members think about Foundation Medicine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Foundation Medicine (NASDAQ:FMI)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $35.00 (30.28% downside)

Consensus Price Target History for Foundation Medicine (NASDAQ:FMI)

Price Target History for Foundation Medicine (NASDAQ:FMI)

Analysts' Ratings History for Foundation Medicine (NASDAQ:FMI)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017BTIG ResearchUpgradeNeutral -> Buy$39.00HighView Rating Details
4/3/2017William BlairReiterated RatingBuyLowView Rating Details
3/7/2017Janney Montgomery ScottUpgradeSell -> Neutral$31.00N/AView Rating Details
11/3/2016Benchmark Co.DowngradeBuy -> HoldN/AView Rating Details
8/3/2016J P Morgan Chase & CoReiterated RatingHold$25.00N/AView Rating Details
5/4/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
2/26/2016The Goldman Sachs Group, Inc.Lower Price TargetNeutral$17.00 -> $15.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Foundation Medicine (NASDAQ:FMI)

Earnings by Quarter for Foundation Medicine (NASDAQ:FMI)

Earnings History by Quarter for Foundation Medicine (NASDAQ FMI)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017($1.06)($0.90)$37.99 million$42.66 millionViewN/AView Earnings Details
8/1/2017Q2 2017($1.08)($1.24)$34.94 million$35.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($1.02)($1.31)$29.07 million$26.32 millionViewListenView Earnings Details
2/22/2017Q416($0.96)($1.02)$29.23 million$28.80 millionViewListenView Earnings Details
11/2/2016Q316($0.88)($0.90)$28.70 million$29.43 millionViewN/AView Earnings Details
8/2/2016Q216($0.79)($0.84)$26.72 million$28.24 millionViewN/AView Earnings Details
5/3/2016Q116($0.72)($0.50)$25.20 million$30.40 millionViewN/AView Earnings Details
2/23/2016Q415($0.67)($0.55)$25.76 million$26.10 millionViewListenView Earnings Details
11/3/2015Q315($0.56)($0.60)$24.04 million$25.40 millionViewListenView Earnings Details
7/29/2015Q215($0.56)($0.98)$24.44 million$22.50 millionViewListenView Earnings Details
5/11/2015Q115($0.53)($0.59)$21.00 million$19.30 millionViewListenView Earnings Details
2/24/2015Q314($0.53)($0.47)$18.05 million$18.70 millionViewListenView Earnings Details
11/5/2014Q3($0.49)($0.46)$15.60 million$16.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.50)($0.49)$13.39 million$14.50 millionViewN/AView Earnings Details
5/7/2014Q114($0.48)($0.44)$11.33 million$11.45 millionViewN/AView Earnings Details
2/25/2014Q413($0.43)($0.48)$9.01 million$9.66 millionViewN/AView Earnings Details
11/6/2013($0.51)($3.51)$6.92 million$8.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Foundation Medicine (NASDAQ:FMI)
Current Year EPS Consensus Estimate: $-4.43 EPS
Next Year EPS Consensus Estimate: $-3.82 EPS

Dividends

Dividend History for Foundation Medicine (NASDAQ:FMI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Foundation Medicine (NASDAQ FMI)

Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 32.29%
Insider Trades by Quarter for Foundation Medicine (NASDAQ:FMI)
Institutional Ownership by Quarter for Foundation Medicine (NASDAQ:FMI)

Insider Trades by Quarter for Foundation Medicine (NASDAQ FMI)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/2/2017Jason RyanCFOSell9,731$50.00$486,550.00View SEC Filing  
10/13/2017Steven J KafkaCOOSell3,361$44.62$149,967.82View SEC Filing  
10/12/2017Jason RyanCFOSell1,152$45.05$51,897.60View SEC Filing  
10/2/2017Jason RyanCFOSell3,154$38.80$122,375.20View SEC Filing  
10/2/2017Michael J PelliniDirectorSell4,349$38.80$168,741.20View SEC Filing  
10/2/2017Robert W HessleinSVPSell2,165$38.80$84,002.00View SEC Filing  
10/2/2017Steven J KafkaCOOSell3,201$38.80$124,198.80View SEC Filing  
10/2/2017Vincent A MillerInsiderSell2,944$38.80$114,227.20View SEC Filing  
8/9/2017David DalyInsiderSell46,872$39.50$1,851,444.00View SEC Filing  
8/9/2017Michael J PelliniDirectorSell30,000$39.52$1,185,600.00View SEC Filing  
8/8/2017Krishna YeshwantDirectorSell4,800$40.01$192,048.00View SEC Filing  
8/4/2017Krishna YeshwantDirectorSell18,072$36.85$665,953.20View SEC Filing  
7/14/2017Steven J KafkaCOOSell11,781$39.15$461,226.15View SEC Filing  
7/13/2017Jason RyanCFOSell5,084$39.77$202,190.68View SEC Filing  
7/6/2017David DalyInsiderSell6,316$38.84$245,313.44View SEC Filing  
7/6/2017Jason RyanCFOSell6,683$38.84$259,567.72View SEC Filing  
7/6/2017Michael J. PelliniDirectorSell15,856$38.84$615,847.04View SEC Filing  
7/6/2017Robert W. HessleinSVPSell5,070$38.84$196,918.80View SEC Filing  
7/6/2017Steven J KafkaCOOSell19,708$38.93$767,232.44View SEC Filing  
7/5/2017Steven J KafkaCOOSell12,310$38.98$479,843.80View SEC Filing  
6/2/2017Jason RyanCFOSell5,573$40.00$222,920.00View SEC Filing  
6/1/2017David DalyInsiderSell555$38.30$21,256.50View SEC Filing  
4/18/2017Jason RyanCFOSell503$34.55$17,378.65View SEC Filing  
4/18/2017Steven J KafkaCOOSell4,405$34.55$152,192.75View SEC Filing  
4/3/2017David DalyInsiderSell2,070$31.96$66,157.20View SEC Filing  
4/3/2017Michael J. PelliniDirectorSell1,700$31.96$54,332.00View SEC Filing  
4/3/2017Robert W. HessleinSVPSell1,233$31.96$39,406.68View SEC Filing  
4/3/2017Steven J. KafkaCOOSell2,157$31.96$68,937.72View SEC Filing  
3/16/2017Jason RyanCFOSell12,500$31.68$396,000.00View SEC Filing  
3/16/2017Robert W HessleinSVPSell6,231$31.67$197,335.77View SEC Filing  
3/8/2017Michael J PelliniDirectorSell40,000$34.30$1,372,000.00View SEC Filing  
2/8/2017Steven J KafkaCOOSell10,415$23.24$242,044.60View SEC Filing  
1/13/2017Jason RyanCFOSell1,777$19.00$33,763.00View SEC Filing  
1/4/2017David DalyInsiderSell5,097$17.91$91,287.27View SEC Filing  
1/4/2017Jason RyanCFOSell4,665$17.74$82,757.10View SEC Filing  
1/4/2017Michael J. PelliniCEOSell14,637$17.67$258,635.79View SEC Filing  
1/4/2017Robert W. HessleinSVPSell4,682$17.74$83,058.68View SEC Filing  
1/4/2017Steven J. KafkaCOOSell8,390$17.72$148,670.80View SEC Filing  
12/1/2016David DalyInsiderSell564$19.95$11,251.80View SEC Filing  
11/22/2016Steven J KafkaCOOSell6,273$23.01$144,341.73View SEC Filing  
10/20/2016Jason RyanCFOSell506$22.45$11,359.70View SEC Filing  
10/20/2016Steven J KafkaCOOSell4,427$23.00$101,821.00View SEC Filing  
10/4/2016David DalyInsiderSell2,045$23.65$48,364.25View SEC Filing  
10/4/2016Michael J. PelliniCEOSell2,629$23.65$62,175.85View SEC Filing  
10/4/2016Robert W. HessleinSVPSell1,220$23.65$28,853.00View SEC Filing  
10/4/2016Steven J. KafkaCOOSell2,135$23.62$50,428.70View SEC Filing  
9/20/2016Steven J KafkaCOOSell9,469$23.70$224,415.30View SEC Filing  
8/19/2016Jason RyanCFOSell13,863$23.92$331,602.96View SEC Filing  
7/5/2016David DalyInsiderSell5,008$17.76$88,942.08View SEC Filing  
7/5/2016Jason RyanCFOSell4,687$17.63$82,631.81View SEC Filing  
7/5/2016Michael J. PelliniCEOSell10,160$17.63$179,120.80View SEC Filing  
7/5/2016Robert W. HessleinSVPSell4,705$17.62$82,902.10View SEC Filing  
7/5/2016Steven J. KafkaCOOSell6,495$17.67$114,766.65View SEC Filing  
6/3/2016David DalyInsiderSell472$21.66$10,223.52View SEC Filing  
4/1/2016Steven J KafkaCOOSell124$18.08$2,241.92View SEC Filing  
4/1/2016Vincent A MillerInsiderSell356$18.08$6,436.48View SEC Filing  
12/1/2015David DalyInsiderSell2,559$16.78$42,940.02View SEC Filing  
11/13/2015Michael J PelliniCEOBuy9,100$16.43$149,513.00View SEC Filing  
6/15/2015Krishna YeshwantDirectorSell183,860$32.98$6,063,702.80View SEC Filing  
4/7/2015Alexis BorisyDirectorSell234,542$50.00$11,727,100.00View SEC Filing  
4/7/2015Roche Holdings IncInsiderBuy15,604,288$50.00$780,214,400.00View SEC Filing  
4/7/2015Rock Ventures Lp ThirdMajor ShareholderSell3,976,278$50.00$198,813,900.00View SEC Filing  
3/5/2015Michael J PelliniCEOSell153,300$47.24$7,241,892.00View SEC Filing  
1/15/2015Steven J KafkaCOOSell15,000$48.38$725,700.00View SEC Filing  
1/12/2015Michael J PelliniCEOSell22,500$51.07$1,149,075.00View SEC Filing  
1/12/2015Robert W HessleinSVPSell7,000$52.11$364,770.00View SEC Filing  
1/12/2015Steven J KafkaCOOSell8,000$51.83$414,640.00View SEC Filing  
1/12/2015Vincent A MillerInsiderSell2,000$53.03$106,060.00View SEC Filing  
1/8/2015Robert W HessleinSVPSell4,000$23.03$92,120.00View SEC Filing  
12/29/2014Michael J PelliniCEOSell12,500$23.91$298,875.00View SEC Filing  
11/17/2014Jason RyanSVPSell3,541$24.90$88,170.90View SEC Filing  
11/14/2014Michael J PelliniCEOSell12,500$24.91$311,375.00View SEC Filing  
10/27/2014Jason RyanSVPSell2,360$25.00$59,000.00View SEC Filing  
10/27/2014Steven J KafkaCOOSell10,000$25.31$253,100.00View SEC Filing  
9/15/2014Jason RyanSVPSell2,361$21.92$51,753.12View SEC Filing  
8/18/2014Michael J PelliniCEOSell12,500$25.29$316,125.00View SEC Filing  
7/22/2014Steven J KafkaCOOSell10,000$27.14$271,400.00View SEC Filing  
7/15/2014Jason RyanSVPSell3,541$27.22$96,386.02View SEC Filing  
7/15/2014Vincent A MillerInsiderSell15,000$27.25$408,750.00View SEC Filing  
7/8/2014Robert W HessleinSVPSell4,000$27.22$108,880.00View SEC Filing  
7/2/2014Michael J PelliniCEOSell15,000$27.42$411,300.00View SEC Filing  
6/26/2014Jason RyanSVPSell1,180$25.00$29,500.00View SEC Filing  
6/26/2014Steven J KafkaCOOSell5,000$25.19$125,950.00View SEC Filing  
6/19/2014Steven J KafkaCOOSell5,000$24.46$122,300.00View SEC Filing  
6/16/2014Jason RyanSVPSell2,361$22.61$53,382.21View SEC Filing  
6/13/2014Krishna YeshwantDirectorSell1,300,000$22.40$29,120,000.00View SEC Filing  
6/5/2014Jason RyanSVPSell10,000$24.06$240,600.00View SEC Filing  
6/5/2014Steven J KafkaCOOSell4,500$24.19$108,855.00View SEC Filing  
5/6/2014Vincent MillerInsiderSell3,000$30.00$90,000.00View SEC Filing  
4/16/2014Jason RyanSVPSell3,541$26.36$93,340.76View SEC Filing  
4/16/2014Vincent MillerInsiderSell30,000$26.86$805,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Foundation Medicine (NASDAQ:FMI)

Latest Headlines for Foundation Medicine (NASDAQ FMI)

Source:
DateHeadline
Reviewing Foundation Medicine (FMI) & Its RivalsReviewing Foundation Medicine (FMI) & Its Rivals
www.americanbankingnews.com - November 17 at 7:22 AM
Foundation Medicine, Inc. (FMI) Expected to Announce Quarterly Sales of $38.57 MillionFoundation Medicine, Inc. (FMI) Expected to Announce Quarterly Sales of $38.57 Million
www.americanbankingnews.com - November 15 at 1:18 PM
Brokerages Expect Foundation Medicine, Inc. (FMI) to Post ($0.98) EPSBrokerages Expect Foundation Medicine, Inc. (FMI) to Post ($0.98) EPS
www.americanbankingnews.com - November 13 at 11:54 AM
Commit To Purchase Foundation Medicine At $40, Earn 12.7% Annualized Using OptionsCommit To Purchase Foundation Medicine At $40, Earn 12.7% Annualized Using Options
www.nasdaq.com - November 9 at 3:43 AM
Options Traders Expect Huge Moves in Foundation Medicine (FMI) StockOptions Traders Expect Huge Moves in Foundation Medicine (FMI) Stock
finance.yahoo.com - November 8 at 6:59 AM
Zacks Investment Research Downgrades Foundation Medicine, Inc. (FMI) to HoldZacks Investment Research Downgrades Foundation Medicine, Inc. (FMI) to Hold
www.americanbankingnews.com - November 7 at 11:10 PM
 Brokerages Anticipate Foundation Medicine, Inc. (FMI) Will Announce Quarterly Sales of $42.20 Million Brokerages Anticipate Foundation Medicine, Inc. (FMI) Will Announce Quarterly Sales of $42.20 Million
www.americanbankingnews.com - November 7 at 4:36 AM
Foundation Medicine, Inc. (FMI) Upgraded by Zacks Investment Research to "Buy"Foundation Medicine, Inc. (FMI) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - November 6 at 11:36 PM
ETFs with exposure to Foundation Medicine, Inc. : November 6, 2017ETFs with exposure to Foundation Medicine, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 10:48 PM
Foundation Medicine, Inc. (FMI) CFO Jason Ryan Sells 9,731 SharesFoundation Medicine, Inc. (FMI) CFO Jason Ryan Sells 9,731 Shares
www.americanbankingnews.com - November 6 at 6:58 PM
The Precision Medicine Stock That's Revolutionizing Cancer TreatmentThe Precision Medicine Stock That's Revolutionizing Cancer Treatment
finance.yahoo.com - November 3 at 12:14 PM
Foundation Medicine, Inc. :FMI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Foundation Medicine, Inc. :FMI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 12:14 PM
Notable Thursday Option Activity: FMI, TOL, PI - NasdaqNotable Thursday Option Activity: FMI, TOL, PI - Nasdaq
www.nasdaq.com - November 2 at 8:03 PM
Edited Transcript of FMI earnings conference call or presentation 1-Nov-17 8:30pm GMTEdited Transcript of FMI earnings conference call or presentation 1-Nov-17 8:30pm GMT
finance.yahoo.com - November 2 at 8:03 PM
Foundation Medicine Announces 2017 Third Quarter Results and Recent HighlightsFoundation Medicine Announces 2017 Third Quarter Results and Recent Highlights
finance.yahoo.com - November 1 at 7:55 PM
Foundation Medicine reports 3Q lossFoundation Medicine reports 3Q loss
finance.yahoo.com - November 1 at 7:55 PM
Foundation Medicine, Inc. (FMI) Issues Quarterly  Earnings Results, Beats Estimates By $0.16 EPSFoundation Medicine, Inc. (FMI) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS
www.americanbankingnews.com - November 1 at 5:47 PM
Head to Head Analysis: Foundation Medicine (FMI) and Its PeersHead to Head Analysis: Foundation Medicine (FMI) and Its Peers
www.americanbankingnews.com - November 1 at 1:22 AM
Head-To-Head Analysis: Foundation Medicine (FMI) and Its PeersHead-To-Head Analysis: Foundation Medicine (FMI) and Its Peers
www.americanbankingnews.com - October 30 at 11:24 PM
Foundation Medicine, Inc. (FMI) Given Average Rating of "Hold" by AnalystsFoundation Medicine, Inc. (FMI) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 27 at 1:30 AM
Foundation Medicine, Inc. (FMI) to Release Quarterly Earnings on TuesdayFoundation Medicine, Inc. (FMI) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 24 at 9:00 AM
Noteworthy Monday Option Activity: FMI, NKE, CRUSNoteworthy Monday Option Activity: FMI, NKE, CRUS
www.nasdaq.com - October 23 at 4:33 PM
Contrasting Alkermes PLC (ALKS) and Foundation Medicine (FMI)Contrasting Alkermes PLC (ALKS) and Foundation Medicine (FMI)
www.americanbankingnews.com - October 21 at 8:28 PM
Foundation Medicine, Inc. (FMI) CFO Jason Ryan Sells 1,152 SharesFoundation Medicine, Inc. (FMI) CFO Jason Ryan Sells 1,152 Shares
www.americanbankingnews.com - October 16 at 7:40 PM
Steven J. Kafka Sells 3,361 Shares of Foundation Medicine, Inc. (FMI) StockSteven J. Kafka Sells 3,361 Shares of Foundation Medicine, Inc. (FMI) Stock
www.americanbankingnews.com - October 16 at 7:40 PM
, a Comprehensive Genomic Profiling Assay for Advancing Precision Cancer Care - Business Wire (press release), a Comprehensive Genomic Profiling Assay for Advancing Precision Cancer Care - Business Wire (press release)
www.businesswire.com - October 16 at 7:06 PM
Foundation Medicine to Present Validation for FoundationOne CDx™, a Comprehensive Genomic Profiling Assay for Advancing Precision Cancer CareFoundation Medicine to Present Validation for FoundationOne CDx™, a Comprehensive Genomic Profiling Assay for Advancing Precision Cancer Care
finance.yahoo.com - October 16 at 7:06 PM
Zacks: Brokerages Expect Foundation Medicine, Inc. (FMI) to Announce -$1.07 EPSZacks: Brokerages Expect Foundation Medicine, Inc. (FMI) to Announce -$1.07 EPS
www.americanbankingnews.com - October 16 at 6:26 PM
Foundation Medicine Announces Timing for Third Quarter 2017 Financial Results and Conference CallFoundation Medicine Announces Timing for Third Quarter 2017 Financial Results and Conference Call
finance.yahoo.com - October 12 at 7:34 PM
Foundation Medicine Appoints Tom Civik as Chief Commercial Officer - Business Wire (press release)Foundation Medicine Appoints Tom Civik as Chief Commercial Officer - Business Wire (press release)
www.businesswire.com - October 10 at 9:36 PM
Is This the Best Precision Medicine Stock to Buy?Is This the Best Precision Medicine Stock to Buy?
finance.yahoo.com - October 10 at 9:35 PM
Robert W. Hesslein Sells 2,165 Shares of Foundation Medicine, Inc. (FMI) StockRobert W. Hesslein Sells 2,165 Shares of Foundation Medicine, Inc. (FMI) Stock
www.americanbankingnews.com - October 4 at 8:48 PM
Insider Selling: Foundation Medicine, Inc. (FMI) Insider Sells 2,944 Shares of StockInsider Selling: Foundation Medicine, Inc. (FMI) Insider Sells 2,944 Shares of Stock
www.americanbankingnews.com - October 4 at 8:30 PM
Foundation Medicine, Inc. (FMI) CFO Jason Ryan Sells 3,154 SharesFoundation Medicine, Inc. (FMI) CFO Jason Ryan Sells 3,154 Shares
www.americanbankingnews.com - October 4 at 8:30 PM
Foundation Medicine, Inc. (FMI) COO Steven J. Kafka Sells 3,201 SharesFoundation Medicine, Inc. (FMI) COO Steven J. Kafka Sells 3,201 Shares
www.americanbankingnews.com - October 4 at 8:28 PM
Foundation Medicine, Inc. (FMI) Director Michael J. Pellini Sells 4,349 SharesFoundation Medicine, Inc. (FMI) Director Michael J. Pellini Sells 4,349 Shares
www.americanbankingnews.com - October 4 at 8:28 PM
Lifshitz & Miller LLP Announces Investigation of Foundation Medicine, Inc., Health Insurance Innovations, Inc., Juno ... - PR Newswire (press release)Lifshitz & Miller LLP Announces Investigation of Foundation Medicine, Inc., Health Insurance Innovations, Inc., Juno ... - PR Newswire (press release)
www.prnewswire.com - October 4 at 5:45 AM
Lifshitz & Miller LLP Announces Investigation of Foundation Medicine, Inc., Health Insurance Innovations, Inc., Juno Therapeutics, Inc., LendingClub Corporation, MiMedx Group, Inc., Ooma, Inc. and SCANA CorporationLifshitz & Miller LLP Announces Investigation of Foundation Medicine, Inc., Health Insurance Innovations, Inc., Juno Therapeutics, Inc., LendingClub Corporation, MiMedx Group, Inc., Ooma, Inc. and SCANA Corporation
finance.yahoo.com - October 4 at 5:45 AM
Foundation Medicine Receives Approval from the State of New York for its FoundationACT Liquid Biopsy Assay - Business Wire (press release)Foundation Medicine Receives Approval from the State of New York for its FoundationACT Liquid Biopsy Assay - Business Wire (press release)
www.businesswire.com - October 3 at 8:29 AM
FOUNDATION MEDICINE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of Deadline in Class Action Lawsuit Against Foundation Medicine, Inc. - (FMI)FOUNDATION MEDICINE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of Deadline in Class Action Lawsuit Against Foundation Medicine, Inc. - (FMI)
finance.yahoo.com - October 2 at 2:30 PM
Foundation Medicine, Inc. breached its 50 day moving average in a Bearish Manner : FMI-US : September 27, 2017Foundation Medicine, Inc. breached its 50 day moving average in a Bearish Manner : FMI-US : September 27, 2017
finance.yahoo.com - October 2 at 2:30 PM
Foundation Medicine Receives Approval from the State of New York for its FoundationACT Liquid Biopsy AssayFoundation Medicine Receives Approval from the State of New York for its FoundationACT Liquid Biopsy Assay
finance.yahoo.com - October 2 at 2:30 PM
Foundation Medicine, Inc. (FMI) Receives Average Recommendation of "Hold" from BrokeragesFoundation Medicine, Inc. (FMI) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 1 at 11:14 PM
$38.22 Million in Sales Expected for Foundation Medicine, Inc. (FMI) This Quarter$38.22 Million in Sales Expected for Foundation Medicine, Inc. (FMI) This Quarter
www.americanbankingnews.com - September 30 at 11:52 AM
FOUNDATION MEDICINE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of Deadline in Class Action Lawsuit Against Foundation Medicine, Inc ...FOUNDATION MEDICINE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of Deadline in Class Action Lawsuit Against Foundation Medicine, Inc ...
www.businesswire.com - September 27 at 6:20 PM
DEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against Foundation Medicine, Inc. and Encourages Investors with Losses to Contact the FirmDEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against Foundation Medicine, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 25 at 4:47 PM
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Foundation Medicine, Inc. (FMI)Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Foundation Medicine, Inc. (FMI)
finance.yahoo.com - September 25 at 4:47 PM
DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Foundation Medicine, Inc. and Reminds Investors with Losses to Contact the FirmDEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Foundation Medicine, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 25 at 4:47 PM
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Foundation Medicine, Inc. (FMI) & Lead Plaintiff Deadline: September 26, 2017DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Foundation Medicine, Inc. (FMI) & Lead Plaintiff Deadline: September 26, 2017
finance.yahoo.com - September 25 at 11:11 AM
DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of Foundation Medicine, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 26, 2017 - FMIDEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of Foundation Medicine, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 26, 2017 - FMI
finance.yahoo.com - September 25 at 11:11 AM

Social Media

Financials

Chart

Foundation Medicine (NASDAQ FMI) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.